GenAssist Ltd (GenAssist), a pioneering gene-editing biotechnology company for genome medicines, released six posters for presentation at the ESGCT 31st Annual Congress, which is held from October 22-25, 2024, in Rome, Italy. Several latest advancements in base editing, DMD, and AAV vector design were featured by poster presentations from GenAssist at ESGCT, which covered a […]
On September 06, 2024, GenAssist Ltd (GenAssist), announced that the first DMD patient has been successfully dosed with its base editing drug, GEN6050X injection, in an investigator-initiated trial (IIT). “To date, no gene editing drug has entered clinical trials for DMD indication. This first-in-human dosing marks that DMD treatment has entered the gene editing era”,
On July 29, 2024, Suzhou GenAssist Therapeutical Co., Ltd, the operation entity of GenAssist Ltd (GenAssist), announced that Pre-IND (PIND) meeting request for its first base editing DMD drug, GEN6050X, has be submitted to NMPA. Previously, the PIND meeting to FDA was held in April 2023. The PIND filing to FDA and NMPA indicated the
On May 30, 2024, Suzhou GenAssist Therapeutical Co., Ltd, the operation entity of GenAssist Ltd (GenAssist), announced that the IIT(NCT06392724) kickoff meeting for its first base editing DMD drug, GEN6050X, has be successfully held in Peking Union Medical College Hospital (PUMCH). This program is sponsored by Suzhou GenAssist Therapeutics and led by Professor Yi Dai,
GenAssist Therapeutics successfully completed a virtual meeting with the TREAT-NMD Advisory Committee for its first base editing product on September 29, 2023. Eighteen representatives, including distinguished preclinical and clinical experts in Duchenne Muscular Dystrophy (DMD) therapy, as well as DMD representatives attended this meeting. A comprehensive review and advice were received on November 13 after
Recently, the team led by Professor Xing Chang, West Lake University, published an article titled “Efficient exon skipping by base-editor-mediated abrogation of exonic splicing enhancers” in Cell Reports. In this paper, Han Q. et al employed Targeted AID-mediated mutagenesis (TAM) cytosine base editor (CBE-TAM) to edit various hotspot mutations of DMD gene in vitro. High
On July 9, 2021, GenAssist has successfully closed a multi-million RMB Pre-Series A financing , bringing the total raised funds to nearly 100 million RMB. The round was led by Sequoia Capital China Fund, with participation from Westlake University Industrial Investment, Suzhou New District Industrial Investment, and the Wang Jiaquan Family Fund. Existing shareholder of
Recently, GenAssist, which is the first company in China to develop gene therapy drugs using base editing technology, announced the closing of a multi-million dollar Series A financing. The round was led by AstraZeneca-CICC Healthcare Industry Fund, with participation from Baidu Ventures (BV), a well-known equity investment institution, and existing shareholder Sequoia China, who continued
GenAssist Completes Multi-Million Dollar Series A Financing Read More »
Recently, Suzhou GenAssisit Therapeutics Co.,Ltd. (hereinafter referred to as “GenAssist”) announced that its first base editing product, GEN6050, has submitted a pre-investigational new drug (Pre-IND) application to the FDA and has been accepted. GEN6050 is an in vivo base editing drug targeting exon 50 skipping for the treatment of Duchenne Muscular Dystrophy (DMD). The drug
Pre-IND application of GenAssist’s First DMD Drug was Accepted by the US FDA! Read More »
Senior pharmacology and toxicology advisor
Pharmacology, Shang University of Traditional Chinese Medicine.
Senior Vice General Manager at Shanghai InnoStar Biotechnology Co., Ltd.
More than 20 years in preclinical pharmacology and toxicology evaluation of new drugs.
Senior Scientific Advisor
Ph.D., Molecular Cell Biology and Bioengineering, Max Planck Research School.
Senior Director of genome engineering department, AstraZeneca, Gothenburg, Sweden.
More than 10 years’ experience in gene editing tool and drug development.
Senior Clinical Physician Advisor
Ph.D. , Peking Union Medical College, Tsinghua University.
Associate Chief physician. Neurology Department. Peking Union Medical College Hospital, Beijing.
Member of the Neurology Branch of the Chinese Medical Association.
Member of the DMD/BMD Study Group of the Chinese Rare Disease Alliance.
Specializes in complex and rare neurological disorders, gene diagnosis of monogenic.
Senior strategic Advisor
Over 30 years of experience in drug discovery, clinical translation, clinical practice, and operational management Former President of Chongqing Medical and Pharmaceutical College.
Ex-Vice President of the Technical Center at Fosun Pharma.
Senior Biostatistics Advisor
Ph.D. Biostatistics, University of Michigan, USA.
Bettyann Asche Murray Distinguished Professor, Deputy Chair.
Department of Biostatistics, University of Texas, MD Anderson Cancer Center.
Inventor of Bayesian Optimal lnterval PhaseⅠ/ⅡTrial Design (BOlN12); Participated in clinical trial design of many anti-cancer treatment.
Co-funder, Senior scientific Advisor
Ph.D. , Pathology, Ohio State University
Associate Professor at West Lake University, Young Scientist in the 973 Program
Thousand Youth Talents Program, National Outstanding Young Scientist
Inventor of Targeted AID-mediated Mutagenesis (TAM) base editor
CEO, Co-Founder
Ph.D. , Immunology, Shanghai Jiao Tong University.
MBA, Manchester Business School.
Over 20 years of experience in pharmaceutical industry, covering R&D, BD, Investment and Incubation.
Quality management advisor
Former Director of the Quality Assurance Department and Laboratory at the Shanghai Institute of Biological Products
Research and establishment of quality standards for various viral bioproducts as well as registration applications
Committee Member of the Chinese Pharmacopoeia Commission,
Expert Member of the Shanghai Science and Technology Commission
Committee Member of the Quality Management Committee of the Shanghai Medical Industry Association
Member of the New Technology/Skills Professional Committee.